Search results
PROMOTED
Author(s):
Nicolas M Van Mieghem
,
Kendra J Grubb
,
David Hildick-Smith
,
et al
Start date:
Mar 26, 2024
Author(s):
Upul Wickramarachchi
Added:
2 years ago
In this video, Dr Upul Wickramarachchi (Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK) discusses the clinical outcomes of drug-coated balloon angioplasty treated patients versus drug-eluting stent treated patients for de novo coronary artery disease in all vessel sizes.
Questions
1. What question does this study aim to address?
2. What was the design, patient cohort…
View more
Author(s):
Upul Wickramarachchi
,
Simon Eccleshall
Added:
3 years ago
Percutaneous coronary interventional techniques and devices have evolved enormously since Gruntzig performed his first coronary angioplasty in 1977. 1 It is now the norm to treat patients with both acute coronary syndrome and stable coronary artery disease with drug-eluting stents. We intend to review the evidence and discuss potential benefits of drug-coated balloon-only angioplasty. These…
View more
Author(s):
Robert A Byrne
,
Eric Eeckhout
,
Gennaro Sardella
,
et al
Added:
3 years ago
Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are established strategies for revascularisation in patients with coronary artery disease. While CABG was the standard of care for patients with multivessel disease, the introduction of baremetal stents (BMSs) and, later, drug-eluting stents (DESs) has led to an increased use of PCI in these more challenging cases…
View more
Author(s):
Raban Jeger
,
Thomas Nestelberger
Added:
3 years ago
Coronary artery disease (CAD) remains a major cause of morbidity and mortality despite major improvements in primary and secondary prevention strategies. Percutaneous coronary intervention (PCI) or surgical revascularisation may be indicated in many patients with acute or stable CAD.1
Since the first coronary intervention using catheter mounted balloons, percutaneous treatment of CAD has evolved…
View more
Bioresorbable Scaffolds
Author(s):
Sidakpal Panaich
,
Theodore Schreiber
,
Cindy Grines
Added:
3 years ago
Article
Author(s):
Robert A Byrne
,
Shmuel Banai
,
Roisin Colleran
,
et al
Added:
3 years ago
Newer generation polymeric metallic drug-eluting stents (DES) have shown improved efficacy and safety compared with bare-metal stents and first-generation DES, improving patient outcomes after percutaneous coronary intervention (PCI) and facilitating the treatment of more complex coronary disease.1 However, clinical outcomes in certain lesion and patient subsets remain suboptimal. Procedural and…
View more
Author(s):
Ehrin J Armstrong
,
Stephen W Waldo
Added:
3 years ago
Patients with diabetes mellitus (DM) have an increased prevalence of coronary artery disease (CAD) and are more likely to require coronary revascularisation than patients without DM.1 Similar to the general population, CAD remains the most frequent cause of death among patients with DM.2 As the prevalence of DM continues to rise worldwide, the appropriate management and method of…
View more
Author(s):
Nienke S van Ditzhuijzen
,
Jurgen M Ligthart
,
Nico Bruining
,
et al
Added:
3 years ago
The indications for percutaneous coronary intervention (PCI) have expanded steadily during the past years. After the days of the revascularisation of obstructive coronary artery disease (CAD) by balloon angioplasty,1 the introduction of coronary stents has essentially contributed to PCI being one of the most frequently performed invasive therapeutic procedures worldwide. Bare metal stents (BMS)…
View more
Author(s):
Angela Hoye
,
Scot Garg
Added:
3 years ago
Coronary artery bifurcations are at an increased risk of the development of coronary atherosclerosis because of turbulent flow and low shear stress. Bifurcation lesions account for between 8% and 22% of all percutaneous coronary interventions (PCI) and have long posed a problem for interventional cardiologists.
Published data show bifurcation lesions treated using bare metal stents (BMS) have…
View more